TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02291289

Intervention type: DRUG
Group type: OTHER
Intervention: Fluoropyrimidine (5-FU/LV or capecitabine)
Description: Per Investigator's discretion: 5-FU 1600-2400 mg/m\^2 administered via 46-hour IV infusion on Day 1 of every 2-week cycle and LV 400 mg/m\^2 administered via a 2-hour infusion on Day 1 every 2 weeks or 1000 mg/m\^2 twice-daily capecitabine (BID) by mouth given days 1-14 every 2 weeks. The chosen fluoropyrimidine should be administered in accordance with local prescribing information.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 800 mg atezolizumab via 60-minute IV infusion on Day 1 of every 2-week cycle, or a fixed dose of 840 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 800 mg atezolizumab via 60-minute IV infusion on Day 1 of every 2-week cycle, or a fixed dose of 840 mg

Intervention type: DRUG
Group type: OTHER
Intervention: Atezolizumab
Description: 800 mg atezolizumab via 60-minute IV infusion on Day 1 of every 2-week cycle, or a fixed dose of 840 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: 960 mg vermurafenib BID by mouth

Intervention type: DRUG
Group type: OTHER
Intervention: Vemurafenib
Description: 960 mg vermurafenib BID by mouth

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: 5 mg/kg bevacizumab via 15-30 minute IV infusion on Day 1 of every 2-week cycle per local prescribing information

Intervention type: DRUG
Group type: OTHER
Intervention: Bevacizumab
Description: 5 mg/kg bevacizumab via 15-30 minute IV infusion on Day 1 of every 2-week cycle per local prescribing information

Intervention type: DRUG
Group type: OTHER
Intervention: Bevacizumab
Description: 5 mg/kg bevacizumab via 15-30 minute IV infusion on Day 1 of every 2-week cycle per local prescribing information

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 5 mg/kg bevacizumab via 15-30 minute IV infusion on Day 1 of every 2-week cycle per local prescribing information
Study: NCT00167531

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: assisted overground walking
Description: 30 minutes per day of overground walking with the assistance of one therapist
Study: NCT02291289

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: 5 mg/kg bevacizumab via 15-30 minute IV infusion on Day 1 of every 2-week cycle per local prescribing information

Intervention type: DRUG
Group type: OTHER
Intervention: Bevacizumab
Description: 5 mg/kg bevacizumab via 15-30 minute IV infusion on Day 1 of every 2-week cycle per local prescribing information

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: 5 mg/kg bevacizumab via 15-30 minute IV infusion on Day 1 of every 2-week cycle per local prescribing information

Intervention type: DRUG
Group type: OTHER
Intervention: Bevacizumab
Description: 5 mg/kg bevacizumab via 15-30 minute IV infusion on Day 1 of every 2-week cycle per local prescribing information

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: 5 mg/kg bevacizumab via 15-30 minute IV infusion on Day 1 of every 2-week cycle per local prescribing information
Study: NCT02832960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxine
Description: The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects \<50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is \<0.4 mU/L, dose will be reduced by 25 mcg; TSH \>=0.4 and \<4.6 mU/L, no change to dose; TSH \>=4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).
Study: NCT03615482

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V114
Description: Single 0.5 mL injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V114
Description: Single 0.5 mL injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QIV
Description: Single 0.5 mL injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QIV
Description: Single 0.5 mL injection
Study: NCT01618656

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-04457845
Description: Study medication will be administered at 4mg by mouth daily for four weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill
Study: NCT02734121

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pre-consultation educational group intervention
Description: Incorporates the key components of shared decision-making and decision support with the philosophy of delivering supportive care to cancer patients.~* Surgeon (40 mins): treatment options for breast reconstruction with indications/ contraindications, advantages / disadvantages, expected post-operative course, aesthetic result and complications with probabilities~* Registered nurse (20 mins): preparing for surgery, postoperative recovery and how to navigate the health care system~* Social worker (30 mins): values clarification exercise~* Breast reconstruction patient volunteers (30 mins) questions and answers about their personal experience
Study: NCT03215472

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DASH Cloud
Description: With DASH Cloud, the investigators will ask participants to track their diet daily using a commercial diet tracking app. The investigators will retrieve the diet data on our DASH Cloud platform and provide tailored feedback about a participant's DASH adherence via fully automated daily or weekly text messages. These feedback messages will describe both an individual's absolute performance and change over time. The investigators also include theory-driven tailored content that reinforces successes, offers motivational strategies, and offers short behavior change tips.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritionix Track app
Description: DASH Light Control participants will be asked to use the Nutritionix app daily and receive publicly available written materials on the DASH diet.
Study: NCT03133481

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adductor Canal Nerve Block
Description: Adductor Canal never technique

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Femoral Nerve Block
Description: Traditional technique
Study: NCT01450371

Intervention type: DEVICE
Intervention: Interferential
Description: The individuals are treated acutely with IES during 30 min, providing a continuous flow of symmetrical rectangular interferential current biphasic pulses using bipolar electrodes with two channels and a slope of 1/5/1. The fixed current is adjusted to 4000 Hz, with the current AMF at 100 Hz and an AMF variation of 25 Hz (25% of AMF).

Intervention type: DEVICE
Intervention: Interferential Placebo
Description: The same instructions and electrode positions were provided to the placebo, although the equipment did not provide any stimulation current
Study: NCT02029430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50 mg/m2 aldoxorubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg/m2 aldoxorubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 150 mg/m2 aldoxorubicin
Study: NCT03976856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GB226
Description: Geptanolimab, 210mg，q2w，ivgtt.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib
Description: Fruquintinib, 3mg or 4mg or 5mg, qd.po. 3 weeks-on,1 week-off
Study: NCT03498872

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AMPfoot 4.0
Description: The novel prosthetic device, i.e. AMPfoot 4.0, was tested during walking in amputees. A dual-task was conducted and non-invasive electro-encephalography was used to investigate neural dynamics.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AMPfoot 4.0
Description: The novel prosthetic device, i.e. AMPfoot 4.0, was tested during walking in amputees. A dual-task was conducted and non-invasive electro-encephalography was used to investigate neural dynamics.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No intervention
Description: The control group included healthy subjects. Comparisons were made between amputees and able-bodied individuals.
Study: NCT02832960

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug. Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg.
Study: NCT02929472

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical exercise
Description: The intervention group (INT, n = 17, 7 boys) who attended at least 75% of PA classes and met more than 50% of food goals.The exercise sessions took 90 minutes, in order to assure at least 60 minutes of physical exercise, during 12 weeks. The sessions were always taught by the same staff, and were composed of: 10 minutes of warm-up; 30 minutes of circuit training; 15-minute of pre-sports and recreational games;and 5 minutes resting activities.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: without physical exercise
Description: The control one (CONT, n = 18, 6 boys), with a minimum or less than 49% attendance in PA classes, and were not involved in the nutrition education program.
Study: NCT00609557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: duloxetine
Description: Weeks 0-2 placebo Weeks 2-3 30mg duloxetine Weeks 3-4 60mg duloxetine Weeks 4-12 60-90mg duloxetine Week 13 30 mg duloxetine Week 14 stop
Study: NCT01166529

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EUS-guided Celiac Plexus Neurolysis
Description: All patients will receive anesthesia. The linear echo-endoscope will be advanced into the proximal stomach. It will be noted whether the tumor is seen in the celiac axis, if there is flow in the celiac artery, and if the celiac ganglia are seen. The celiac ganglia will be injected directly with 10cc of 0.25% bupivicaine followed by 10cc of 98% dehydrated alcohol. If the celiac ganglia cannot be identified, the posterior and anterior aspects of celiac artery take-off will be injected in a similar manner (twice the volume). Flow in the celiac axis will be confirmed. All injections will be performed with a standard EUS injection needle made especially for CPN . Prior to injection, aspiration will be performed through the needle to ensure that no blood is aspirated.
Study: NCT03940781

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: comprehensive rehabilitation
Description: oropharyngeal rehabilitation, cardiopulmonary rehabilitation, and therapeutic exercise
Study: NCT01942135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib 125 mg/day orally continuously dosed for 3 weeks followed by 1 week off; repeated at each subsequent cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant 500 mg intramuscularly on Days 1 and 15 of Cycle 1, and then on Day 1 of each subsequent 28 day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo orally continuously dosed for 3 weeks followed by 1 week off; repeated at each subsequent cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: Fulvestrant 500 mg intramuscularly on Days 1 and 15 of Cycle 1, and then on Day 1 of each subsequent 28 day cycle.
Study: NCT03615482

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Matching Placebo for V114
Description: Single 0.5 mL injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Matching Placebo for V114
Description: Single 0.5 mL injection
Study: NCT04520958

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness of Breath
Description: Mindfulness of Breath consisted of instruction in focused attention on the breath and metacognitive monitoring and acceptance of discursive thoughts, negative emotions, and pain.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness of Pain
Description: Mindfulness of Pain consisted of instruction in how to (1) zoom in to deconstruct pain into its constituent physical sensations and precisely map each sensation's spatial location, (2) use mindful breathing to zoom out and broaden the field of attention to include previously neglected sensory elements (i.e., spaces within the body that were absent of sensation and pleasant sensations), and (3) shift attention from unpleasant sensations to neutral/pleasant sensations or experiences.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-Behaviorally Based Pain Psychoeducation
Description: Cognitive-Behaviorally Based Pain Psychoeducation consisted of psychoeducation about the link between thoughts, emotions, and behavior and provided instruction in the use logic to dispute maladaptive thoughts about pain that might otherwise exacerbate pain and distress.
Study: NCT04192942

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: protocol of management of major burn in intensive care unit
Description: primary assessment first aid management laboratory investigation radiological investigation surgical intervention
Study: NCT01314781

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: solifenacin
Description: solifenacin 5mg tablet once daily
Study: NCT03072511

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Spotlight on Smoke-Free Living: Mindsets and Decisions
Description: Intervention will consist of elements to help quit smoking. All intervention elements will be informed by Construal Level Theory.
Study: NCT01314781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: solifenacin
Description: solifenacin 5mg tablet once daily

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PFMT and WBVT
Description: pelvic floor muscle and whole body vibration training once a week
Study: NCT03891459

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: spray+ manipulation
Description: Participants in spray+ group received placebo manipulation and were told they sprayed was oxytocin (in fact, it was saline);

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: control manipulation
Description: Participants in control group were told they sprayed saline (in fact, it was saline).
Study: NCT00977691

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PBSC Transplant
Description: PBSC transplant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PBSC Transplant
Description: PBSC transplant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PBSC Transplant
Description: PBSC transplant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: alemtuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: alemtuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: alemtuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: sirolimus
Study: NCT00301964

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00977691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: sirolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: sirolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: cyclophosphamide
Study: NCT02267408

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Warfarin adjustment using the Fearon algorithm
Description: All available historical data will be used to calculate with the Fearon algorithm the individual sensitivity to warfarin and to dose changes as well as lag time until a dose adjustment reaches full effect. Based on this a personal dosing nomogram will be developed and provided to the investigator and to the patients. This nomogram will be used during 6 month but override is possible if the investigator feels that the suggestion from the nomogram is unsafe.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin adjustment using standard dosing
Description: Patients will receive warfarin dosing instructions from a trained nurse using fixed nomograms and computer-based dosing suggestion.
Study: NCT00977691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: cyclophosphamide

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low Dose Irradiation
Description: low dose irradiation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low Dose Irradiation
Description: low dose irradiation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low Dose Irradiation
Description: low dose irradiation
Study: NCT02398825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib
Description: Ponatinib is given orally 30 mg daily, with dose adjustment to 15 mg daily once a BCR-ABL1 level minor or equal to 0.1% (MMR) has been achieved and confirmed in the next test, 4 weeks apart. A return to prior, 30 mg, dose is due in case of return of BCR-ABL1 transcripts level to \> 1%. Dose adjustments for toxicity are detailed in the protocol.
Study: NCT03597893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: intranasally administrated

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intranasally administrated
Study: NCT02529865

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Periurethral injection of autologous ADRCs and adipose tissue
Description: 1 mL of the isolated ADRC is injected into the region of the external urethral sphincter, and another 4 mL of the ADRC and 16mL autologous adipose cells is injected under the urethral mucosa.
Study: NCT00192283

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAIV-T
Description: The total single-dose volume of 0.2 mL was administered intranasally with the spray applicator intended for commercial use (approximately 0.1 mL into each nostril).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single dose of placebo volume of 0.2 mL was administered intranasally with the spray applicator intended for commercial use (approximately 0.1 mL into each nostril).
Study: NCT03347864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-NOTA-RM26
Description: 1.85 MBq per kilogram body weight of 68Ga-NOTA-RM26 were injected into the patients before the PET/CT scans
Study: NCT00285090

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium, Vitamin D

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium,Vitamin D

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium, VitaminD

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill
Study: NCT03072511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal Nicotine Patch
Description: TNP serve as nicotine replacement for individuals who are attempting to stop smoking. They are safe for use and dosing will be determined for each participant based off of manufacturer's recommendations.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Transdermal Nicotine Patch
Description: TNP serve as nicotine replacement for individuals who are attempting to stop smoking. They are safe for use and dosing will be determined for each participant based off of manufacturer's recommendations.
Study: NCT02353117

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Congenital Syphilis Intervention Group
Study: NCT02044484

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-component intervention
Description: The computer-based intervention (CBI) is offered to patients whose viral load exceeds 1000 copies/mL at enrollment.~Counseling is offered to patients whose viral load does not drop 1-log after the first CBI or remains above 200 copies/mL after completing two CBIs.~The behavioral screener will be conducted of all patients at primary care visits. The patient completes the screener before seeing the provider. Responses are given to their provider who can use it in clinical care of the patient.~At primary care visits, all patients are given a palm card containing 1 of 15 empowering messages before they leave the clinic. Messages cover three domains: adhering to antiretroviral therapy, regular care, and safer sex.
Study: NCT00425438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: 0.5 g PO BID from Day 0 to the end of Week 1, followed by 1.0 g PO BID from Weeks 2 through 24, and 0.75 g PO BID from Weeks 32 to 48

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroids
Description: 0.75 to 1.0 mg/kg/d PO (up to 60 kg/day) from Weeks 1 through 4; reduced by 10 mg/day every 2 weeks until dose reaches 40 mg/day, followed by a reduction of 5 mg/day every 2 weeks until dose reaches 10 mg/day up to Week 48

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: 0.75 to 1.0 mg/kg/d PO (up to 60 kg/day) from Weeks 1 through 4; reduced by 10 mg/day every 2 weeks until dose reaches 40 mg/day, followed by a reduction of 5 mg/day every 2 weeks until dose reaches 10 mg/day up to Week 48
Study: NCT04620057

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: butyrate
Description: sodium butyrate (20 mg/kg body weight/day)
Study: NCT00425438

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine
Description: 100 mg PO daily for participants with a body weight of 50 to 70 kg,150 mg PO daily for subjects with a body weight of more than 70 kg up to Week 48

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 0.75 g/m\^2 IV every 4 weeks from Weeks 1 through 4, and 0.5-1.0 g/m\^2 to maintain a minimum WBC count of ≥ 2500 per mm\^3 from Weeks 5 through 24
Study: NCT02089737

Intervention type: DRUG
Intervention: Panitumumab
Description: Panitumumab for intravenous infusion
Study: NCT03511638

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bausch & Lomb DVisc40
Description: Ophthalmic viscosurgical device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Alcon VISCOAT®
Description: Ophthalmic viscosurgical device
Study: NCT02973646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir or Tenofovir
Description: Patients in nucleos(t)ide analogues treatment for 12 weeks group will receive nucleos(t)ide analogs therapy (Entecavir tablet 0.5mg/d or Tenofovir tablet 300mg/d) from Week 25th to 36th.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon Alfa-2B

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon Alfa-2B